Shkreli-Founded Biotech Seen Ripe for Buying as Shares Tumble

Login to Listen
(Bloomberg) -- Retrophin Inc. shares plummeted as much as 32% in early trading on Thursday after an experimental therapy from the drugmaker missed the main and key secondary goals in a late-stage s...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.